| Pharmaceutical Research Report Center |
> Home |
Business Insights have teamed up with global drug discovery experts to bring you a unique series of reports providing in-depth analysis into the future of the drug discovery sector. The Drug Discovery series is a new set of reports that tackle the issues impeding innovation for R&D executives and assess the cutting edge approaches and technologies companies can use to overcome the productivity gap. |
> Introducing a new series of reports Business Insights have teamed up with global drug discovery experts to bring you a unique series of reports providing in-depth analysis into the future of the drug discovery sector. This new set of reports tackle the issues impeding innovation for R&D executives and assess the cutting edge approaches and technologies companies can use to overcome the productivity gap. The R&D productivity crisis In the last five years, on average, fewer than 30 NMEs (new molecular entities) per year have been approved in the US, despite record research and development spending. With key products suffering patent expiry in coming years, there is greater pressure on the pharmaceutical industry to resolve drug discovery bottlenecks and produce more innovative, efficacious and safe drugs. Our new drug discovery portfolio of reports is designed to help R&D executives:
Drug Discovery Series – report titles
|
